⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7897858 | 0.87 | CYP2D6 (0.46) | — | |
| SCHEMBL655664 | 0.85 | KCNH2 (0.47) | — | |
| SCHEMBL27648727 | 0.84 | KCNH2 (0.50) | — | |
| SCHEMBL18783298 | 0.84 | KCNH2 (0.50) | — | |
| SCHEMBL9513948 | 0.84 | KCNH2 (0.50) | — | |
| SCHEMBL22308364 | 0.84 | KCNH2 (0.50) | — | |
| SCHEMBL3477002 | 0.82 | CYP1A2 (0.40) | — | |
| SCHEMBL250764 | 0.81 | — | — | |
| SCHEMBL30022180 | 0.81 | — | — | |
| Ammonia Solution, Strong SCHEMBL28054333 | 0.79 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11708381-B2 | Inhibitors of androgen receptor signaling | XAVIER UNIVERSITY OF LOUISIANA (US) | 2023-07-25 | — | — | US | disclosed |
| US-11701370-B2 | Phosphonium ion channel blockers and methods for use | Nocion Therapeutics, Inc. (US) | 2023-07-18 | — | — | US | disclosed |
| US-20230203053-A1 | HALOGENATED DERIVATIVES OF MORPHINANS AND USES THEREOF | XALUD THERAPEUTICS, INC. (US) | 2023-06-29 | — | — | US | disclosed |
| US-20230203053-A1 | HALOGENATED DERIVATIVES OF MORPHINANS AND USES THEREOF | XALUD THERAPEUTICS, INC. (US) | 2023-06-29 | — | — | US | disclosed |
| US-20220411426-A1 | SUBSTRATE SELECTIVE INHIBITORS OF INSULIN-DEGRADING ENZYME (IDE) AND USES THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2022-12-29 | — | — | US | disclosed |
| US-11530198-B2 | Compositions and methods for treating infections | Vyera Pharmaceuticals, LLC (US) | 2022-12-20 | — | — | US | disclosed |
| US-11072585-B2 | Fluorinated lysyl oxidase-like 2 inhibitors and uses thereof | PHARMAKEA, INC. (US) | 2021-07-27 | — | — | US | disclosed |
| US-11040976-B2 | Substrate selective inhibitors of insulin-degrading enzyme (IDE) and uses thereof | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2021-06-22 | — | — | US | disclosed |
| US-20210130380-A1 | PHOSPHONIUM ION CHANNEL BLOCKERS AND METHODS FOR USE | Nocion Therapeutics, Inc. | 2021-05-06 | — | — | US | disclosed |
| US-20210128589-A1 | PHOSPHONIUM ION CHANNEL BLOCKERS AND METHODS FOR USE | Nocion Therapeutics, Inc. | 2021-05-06 | — | — | US | disclosed |
| US-7754728-B2 | Adenine compound and use thereof | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2010-07-13 | — | — | US | disclosed |
| US-20100105910-A1 | BLOCKING AGENTS FOR ORGANOBORANE COMPOUNDS | DOW GLOBAL TECHNOLOGIES INC. (US) | 2010-04-29 | — | — | US | disclosed |
| US-20100081693-A1 | THIADIAZOLE COMPOUND AND USE THEREOF | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2010-04-01 | — | — | US | disclosed |
| US-20090312312-A1 | Heterobicyclic Metalloprotease Inhibitors | ALANTOS PHARMACEUTICALS HOLDING, INC. (US) | 2009-12-17 | — | — | US | disclosed |
| US-20090291951-A1 | Novel Cyclic Compound Having Pyrimidinylalkylthio Group | SATEN PHARMACEUTICAL CO., LTD. (JP) | 2009-11-26 | — | — | US | disclosed |
| US-7262186-B2 | Substituted pyrazolo[3,4-d] pyrimidinones as a mitotic kinesin inhibitor | MERCK & CO., INC. (US) | 2007-08-28 | — | — | US | disclosed |
| US-7262187-B2 | Substituted oxazolo- and thizaolopyrimidinones as a mitotic kinesin inhibitor | MERCK & CO., INC. (US) | 2007-08-28 | — | — | US | disclosed |
| US-7244723-B2 | Substituted furopyrimidinones as a mitotic kinesin inhibitors | MERCK & CO., INC. (US) | 2007-07-17 | — | — | US | disclosed |
| WO-2004108706-A1 | TRIAZOLE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE DOPAMINE D3 RECEPTOR | ABBOTT GMBH & CO. KG (DE) | 2004-12-16 | — | — | WO | disclosed |
| WO-2002090328-A1 | THE PREPARATION OF SUBSTITUTED PYRIDINES UTILIZING NITRIC AND AN ANHYDRIDE | REILLY INDUSTRIES, INC. (US) | 2002-11-14 | — | — | WO | disclosed |